FEMY Insider Trading Activity and SEC Form 4 Filings
FEMY insider trading summary
Over the past 12 months, insiders at Femasys Inc (FEMY) reported 5 open-market purchases worth $134K by 5 insiders and no sales on SEC Form 4. Net insider buying was $134K.
Latest FEMY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 7, 2026 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | Buy | $10K (3,125 @ $3.20) |
| Aug 7, 2026 | Kathy Lee-Sepsick | Chief Executive Officer | Buy | $50K (15,625 @ $3.20) |
| Aug 7, 2026 | Dov Elefant | Chief Financial Officer | Buy | $50K (15,625 @ $3.20) |
| Aug 7, 2026 | John Charles Canning | Chief Operating Officer | Buy | $14K (4,375 @ $3.20) |
| Aug 7, 2026 | Jeremy Alexander Sipos | Chief Technology Officer | Buy | $10K (3,125 @ $3.20) |
| Jun 23, 2021 | John Dyett | Insider | Buy | $10K (1,000 @ $9.95) |
| Jun 22, 2021 | John Dyett | Insider | Buy | $520K (40,000 @ $13.00) |
| Jun 22, 2021 | Edward R Uzialko | Insider | Buy | $1.3M (100,000 @ $13.00) |
| Jun 22, 2021 | Charles Larsen | Insider | Buy | $91K (7,000 @ $13.00) |
| Jun 22, 2021 | John Q Adams JR | Insider | Buy | $520K (40,000 @ $13.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.